Micro-UltraSound In Cancer - Active Surveillance
- Conditions
- Prostate Cancer
- Registration Number
- NCT05558241
- Lead Sponsor
- University of Alberta
- Brief Summary
This study will compare the two imaging modalities (MRI and micro-ultrasound) during Active Surveillance of prostate cancer (PCa). Progression to clinically significant PCa will be assessed by first taking micro-US targeted samples (while blinded to MRI results), followed by MRI targeted samples, finishing with 12 systematic biopsy cores. The primary goal is to compare microUS to MRI for the detection of ≥GG2 PCa at confirmatory biopsy. This study will also collect blood samples from participants to be used for future biomarker studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 210
- Adult men with Gleason Grade Group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy
- Men who cannot undergo a prostate MRI
- Men who cannot undergo a prostate biopsy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Cancer upgrading during Active surveillance by micro-ultrasound and MRI Immediately after biopsy. The primary outcome will be detection of ≥Grade Group 2 by each biopsy, technique in combination with the systematic biopsy.
- Secondary Outcome Measures
Name Time Method Cancer upgrading during Active surveillance between imagine-guided versus systematic biopsy. Immediately after biopsy. Secondary outcome will compare each imaged-guided biopsy technique to the standard-of-care 12 core systematic biopsy simultaneously obtained.
Trial Locations
- Locations (5)
Humanitas
🇮🇹Milan, Italy
University of California Los Angeles, Department of Urology
🇺🇸Los Angeles, California, United States
Kipnes Urology Centre - Kaye Edmonton Clinic
🇨🇦Edmonton, Alberta, Canada
University of British Columbia
🇨🇦Vancouver, Alberta, Canada
CIUSSS du Nord-de-L'Ile-De-Montreal
🇨🇦Montreal, Quebec, Canada
Humanitas🇮🇹Milan, ItalyNadia Lo IaconoContact+39 0282247744nadia.lo_iacono@cancercenter.humanitas.itNadiaContactGiovanni Lughezzani, MD, MDPrincipal Investigator